Bayer Schering Pharma has highlighted the progress being made by its staff in clinical research jobs on new haemophilia drug development.
The company revealed at the Bayer Schering Pharma Haematology Conference 2010 that its research efforts in this area are currently focused on the advancement of the rFVIIa compound BAY 86-6150 and the site-directed PEGylated BDD-rFVIII BAY 94-9027.
A pivotal phase II/III study of BAY 86-6150 is to be commenced within the next few months after a phase I trial showed the potential of the compound as a treatment for bleeding in haemophilia patients with inhibitors.
Meanwhile, a phase I proof of concept study for BAY 94-9027 is also due to take place before the end of the year.
Dr Georg Lemm, head of clinical development for the haematology product line at Bayer Schering Pharma, said this comes as part of the company's efforts to develop a successor to its Factor VIII product Kogenate Bayer.
He added: "We also aim to expand scientific knowledge and clinical skills that may improve the lives of patients living with haemophilia."
Last month, the firm announced plans to ally with Cancer Research Technology to develop new treatment approaches for gynaecological and oncological diseases.